SCHEMBL2214726

SCHEMBL2214726

O=[C]C1CC(O)CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1983124 1.00
SCHEMBL1983123 1.00
SCHEMBL1028281 1.00
SCHEMBL9073808 0.84
SCHEMBL6444658 0.75
SCHEMBL3782729 0.75
SCHEMBL9069796 0.75
SCHEMBL519001 0.74
Hydrochloric Acid SCHEMBL15539545 0.73
SCHEMBL1676805 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117545850-A Method for ligating polypeptide and oligonucleotide 南洋理工大学 2024-02-09 CN claimed
WO-2020163170-A1 TRAPPING-FREE PARP INHIBITORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-13 WO claimed
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
EP-1808440-A1 Non-covalent inhibitors of urokinase and blood vessel formation Wilex AG (DE) 2007-07-18 EP claimed
EP-1182207-B1 Non-covalent inhibitors of urokinase and blood vessel formation DENDREON CORP (US) 2007-04-18 EP claimed
US-7157596-B2 Inhibitors of serine protease activity of matriptase or MTSP1 DENDREON CORPORATION 2007-01-02 US claimed
US-6777535-B1 USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS ABBOTT LABORATORIES 2004-08-17 US claimed
EP-1421107-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2004-05-26 EP claimed
US-20020037857-A1 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. 2002-03-28 US claimed
WO-2002020475-A2 INHIBITORS OF SERINE PROTEASE ACTIVITY OF MATRIPTASE OR MTSP1 CORVAS INTERNATIONAL, INC. (US) 2002-03-14 WO claimed
EP-1182207-A2 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. (US) 2002-02-27 EP claimed
WO-2002014349-A2 NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION CORVAS INTERNATIONAL, INC. (US) 2002-02-21 WO claimed
WO-2001038397-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
EP-1100814-A2 INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION CORVAS INTERNATIONAL, INC. (US) 2001-05-23 EP claimed
WO-2000005245-A2 INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION CORVAS INTERNATIONAL, INC. (US) 2000-02-03 WO claimed
WO-1995014033-A1 NOVEL DIPEPTIDE DERIVATIVES AKTIEBOLAGET ASTRA (SE) 1995-05-26 WO claimed
WO-1995012605-A1 NOVEL AMINO ACID DERIVATIVES AKTIEBOLAGET ASTRA (SE) 1995-05-11 WO claimed
WO-1995012604-A1 NOVEL AMINO ACID DERIVATIVES AKTIEBOLAGET ASTRA (SE) 1995-05-11 WO claimed